Glialogix Overview

  • Founded
  • 2009
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 2

Glialogix General Information


Developer of therapies for progressive multiple sclerosis. The company's technology is designed to slow the progression of chronic neurodegenerative diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 38 Bayo Vista Avenue
  • Larkspur, CA 94939
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Glialogix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 01-Jan-2013 Completed Startup
1. Grant 11-Feb-2012 00000 Completed Startup
To view Glialogix’s complete valuation and funding history, request access »

Glialogix Executive Team (2)

Name Title Board Seat Contact Info
Mark Moore Ph.D Chief Executive Officer
Thadd Reeder Ph.D Co-Founder & CSO
To view Glialogix’s complete executive team members history, request access »

Glialogix Board Members (2)

Name Representing Role Since
Robert Booth Ph.D Self Board Member 000 0000
Thomas Dietz Ph.D Self Board Member 000 0000
To view Glialogix’s complete board members history, request access »

Glialogix Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BayBio FAST Accelerator/Incubator 000 0000 000000 0
Muscular Dystrophy Association Not-For-Profit Venture Capital Minority 000 0000 000000 0
To view Glialogix’s complete investors history, request access »